The University of Pittsburgh proposes to continue a Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer. The overall goals of the Pittsburgh Head and Neck SPORE are to improve the detection, and treatment of head and neck cancer. The SPORE program consists of four translational research projects in head and neck cancer, two research cores, an administrative core, a developmental research program and a career development program. The University of Pittsburgh Head and Neck SPORE will use an interdisciplinary approach to meet its objectives by carrying out projects with co-investigators in basic, applied and clinical science. It is also organ-specific in that its approach and all projects will test hypotheses about head and neck cancer biology, susceptibility, detection, or treatment. The long-term goal of the Head and Neck SPORE is to conduct clinical studies based on research results from the translational research projects that will serve as the basis for improving the outcome of patients diagnosed with head and neck cancer. The four main projects include: (1) Pathway and GWAS-SNPs: Role in SCCHN Risk, Outcome and Treatment;(2) Inhibition of the STATS Signaling Network;(3) Cellular Immunity and Immune Escape for EGFR Antibody Therapy;and (4) Therapeutic Mechanisms of Co-Targeting EGFR and Src Family Kinases. The three cores will interact closely to assist the main research projects, developmental research projects and the career development investigators in carrying out translational head and neck cancer research. The research cores include: (1) Histology/Tissue Banking and (2) Biostatistics and Informatics. The Administrative Core will solicit feedback from the Internal and External Scientific Advisory Boards and provide scientific, regulatory and fiscal oversight for the SPORE program. The Head and Neck SPORE investigators will work together to synergistically achieve the goals of the program and will also interact with investigators from SPOREs at other institutions to improve the outcome of patients with cancer of the head and neck.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-07
Application #
8118935
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Ujhazy, Peter
Project Start
2002-07-01
Project End
2015-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
7
Fiscal Year
2011
Total Cost
$2,185,000
Indirect Cost
Name
University of Pittsburgh
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Albergotti, William G; Gooding, William E; Kubik, Mark W et al. (2017) Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx. JAMA Otolaryngol Head Neck Surg 143:542-548
Jie, Hyun-Bae; Srivastava, Raghvendra M; Argiris, Athanassios et al. (2017) Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients. Cancer Immunol Res 5:408-416
Kubik, Mark; Mandal, Rajarsi; Albergotti, William et al. (2017) Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery. Head Neck 39:1510-1515
Patel, Snehal G; Carty, Sally E; McCoy, Kelly L et al. (2017) Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 161:168-175
Srivastava, Raghvendra M; Trivedi, Sumita; Concha-Benavente, Fernando et al. (2017) CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res 23:707-716
Concha-Benavente, Fernando; Ferris, Robert L (2017) Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 45:52-59
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Andrews, Lawrence P; Marciscano, Ariel E; Drake, Charles G et al. (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80-96
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2017) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res :
Godse, Neal R; Khan, Nayel; Yochum, Zachary A et al. (2017) TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression. Clin Cancer Res 23:7324-7332

Showing the most recent 10 out of 289 publications